Cartesian Therapeutics, Inc. (RNAC)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenue | 298 | 1,100 | 387 | 33,445 |
| Research and development | 14,869 | 14,674 | 11,400 | 12,661 |
| General and administrative | 7,240 | 8,315 | 6,562 | 7,027 |
| Total operating expenses | 22,109 | 22,989 | 17,962 | 19,688 |
| Operating (loss) income | -21,811 | -21,889 | -17,575 | 13,757 |
| Interest income | 1,748 | 2,015 | 2,573 | 1,195 |
| Change in fair value of forward contract liabilities | - | - | - | - |
| Change in fair value of warrant liabilities | -654 | -1,818 | -5,669 | 3,908 |
| Change in fair value of contingent value right liability | -35,300 | -346 | 15,100 | -2,500 |
| Other (expense) income, net | -5 | - | 250 | 292 |
| Net income (loss) | 15,886 | -17,710 | -24,183 | 13,836 |
| Foreign currency translation adjustment | 12 | 32 | -15 | - |
| Total comprehensive income (loss) | 15,898 | -17,678 | -24,198 | 9,628 |
| Less: undistributed earnings allocable to participating securities, basic | - | - | - | 4,208 |
| Net loss allocable to shares of common stock - basic | - | - | - | 9,628 |
| Basic (in dollars per share) | 0.51 | -0.68 | -1.13 | 0.58 |
| Basic (in shares) | 25,980,262 | 25,902,650 | 21,471,408 | 16,723,479 |
| Diluted (in dollars per share) | 0.5 | -0.68 | -1.13 | 0.54 |
| Diluted (in shares) | 26,447,251 | 25,902,650 | 21,471,408 | 17,791,143 |